Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TTN (Titin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

TTN mutation	Non Small Cell Lung Cancer	TTN mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TTN mutation + IDH2 mutation	Glioma	TTN mutation + IDH2 mutation	Glioma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17)	Glioblastoma	PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17)	Glioblastoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
PIK3CA mutation + TTN mutation + IDH2 mutation	Glioma	PIK3CA mutation + TTN mutation + IDH2 mutation	Glioma	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3	temozolomide gel Sensitive: C3 – Early Trials temozolomide gel Sensitive : C3
TTN 10361-5delT	Chronic Myeloid Leukemia	TTN 10361-5delT	Chronic Myeloid Leukemia	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
TTN D7145H	Esophageal Squamous Cell Carcinoma	TTN D7145H	Esophageal Squamous Cell Carcinoma	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3
TTN mutation	Lung Adenocarcinoma	TTN mutation	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TTN mutation	Melanoma	TTN mutation	Melanoma	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
TP53 mutation + TTN mutation	Lung Cancer	TP53 mutation + TTN mutation	Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3